Endogenous IL-10 protects mice from death during septic peritonitis.

IL-10 production during endotoxic shock is part of a protective mechanism that involves IL-10-induced inhibition of TNF synthesis. We sought to determine the role of IL-10 in septic peritonitis induced by cecal ligation and puncture (CLP). CLP led to a rapid induction of IL-10 mRNA in various organs of C57BI/6 mice. In liver, IL-10 mRNA was detectable within 1 h following CLP, while in spleen and lungs, IL-10 mRNA was detected from 2 to 4 h and onward. IL-10 protein became detectable in plasma 2 h after CLP, reaching peak concentrations after 12 h (12.7 +/- 5.7 ng/ml). Pretreatment (-2 h) with anti-IL-10 mAb resulted in higher plasma TNF levels following CLP when compared with mice treated with control mAb. Plasma IL-1 activity and IFN-gamma remained undetectable in virtually all mice. Anti-IL-10 enhanced mortality after CLP (p < 0.05 by log-rank test). Addition of anti-TNF mAb did not influence the increased mortality associated with anti-IL-10 treatment. Septic peritonitis is associated with sustained production of IL-10 in various organs, which serves to protect the host against lethality.

[1]  P. Barie,et al.  Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis. , 1995, The Journal of infectious diseases.

[2]  M. Feldmann,et al.  Two inhibitors of pro‐inflammatory cytokine release, interleukin‐10 and interleukin‐4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes , 1994, European journal of immunology.

[3]  H. Tilg,et al.  Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. , 1994, Blood.

[4]  K. McMasters,et al.  Endotoxin and tumour necrosis factor do not cause mortality from caecal ligation and puncture. , 1994, Cytokine.

[5]  W. Buurman,et al.  Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein. , 1994, Journal of immunology.

[6]  W. Buurman,et al.  Slow release of soluble TNF receptors by monocytes in vitro. , 1994, Journal of immunology.

[7]  J. Devière,et al.  Interleukin-10 production during septicaemia , 1994, The Lancet.

[8]  T. van der Poll,et al.  Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. , 1994, Journal of immunology.

[9]  H. Tilg,et al.  Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. , 1994, Cytokine.

[10]  M. Denis,et al.  IL-10 neutralization augments mouse resistance to systemic Mycobacterium avium infections. , 1993, Journal of immunology.

[11]  D. Gouma,et al.  LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. , 1993, Journal of immunology.

[12]  D. Leroy,et al.  IFN-gamma involvement in the severity of gram-negative infections in mice. , 1993, Journal of immunology.

[13]  M. Howard,et al.  Interleukin 10 protects mice from lethal endotoxemia , 1993, The Journal of experimental medicine.

[14]  D. Abramowicz,et al.  In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A , 1993, The Journal of experimental medicine.

[15]  P. Abbet,et al.  Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. , 1992, Journal of immunology.

[16]  L. Moldawer,et al.  Type I IL-1 receptor blockade exacerbates murine listeriosis. , 1992, Journal of immunology.

[17]  T. Mosmann,et al.  IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.

[18]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[19]  R. Bone,et al.  The pathogenesis of sepsis. , 1991, Annals of internal medicine.

[20]  H. Langstein,et al.  Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. , 1991, The Journal of clinical investigation.

[21]  M. Fink,et al.  Laboratory models of sepsis and septic shock. , 1990, The Journal of surgical research.

[22]  J. Norton,et al.  Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. , 1989, Surgery.

[23]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[24]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[25]  J. Vincent,et al.  Interleukin-10 as a protective cytokine produced during sepsis , 1996 .

[26]  M. Goldman,et al.  High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. , 1995, The Journal of infectious diseases.

[27]  H. Tilg,et al.  Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. , 1994, Blood.